Lumitin (conbercept) / Chengdu Kanghong Pharma 
Welcome,         Profile    Billing    Logout  
 27 Diseases   27 Trials   27 Trials   307 News 


«12345678»
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Journal:  Intravitreal injection of conbercept for diabetic macular edema complicated with diabetic nephropathy. (Pubmed Central) -  Feb 19, 2024   
    Intravitreal conbercept is safe and effective for the treatment of ICNV. Conbercept has a significant effect in short-term treatment of DME patients with or without DN, and can significantly ameliorate BCVA, CMT and the number of HF, treatment efficacy of DME patients without DN is better than that of DME patients with DN.
  • ||||||||||  Retrospective data, Review, Journal:  Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. (Pubmed Central) -  Jan 30, 2024   
    We found no evidence that any drug increases all-cause mortality compared to control, but estimates were very imprecise. Evidence from RCTs may not apply to real-world practice, where people in need of antiangiogenic treatment are often under-treated, and the individuals exposed to these drugs may be less healthy than trial participants.
  • ||||||||||  Retrospective data, Journal:  Different approaches for treating myopic choroidal neovascularization: a network Meta-analysis. (Pubmed Central) -  Dec 19, 2023   
    Anti-VEGF has the best effect on long-term vision improvement in mCNV patients, using IVB or IVR alone to treat mCNV may be better than IVB or IVR combined with PDT. There is no significant difference in the improvement of visual acuity, macular edema, and CRA in mCNV patients treated with any different anti-VEGF drugs.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
    Journal:  Early effects of intravitreal anti-VEGF agents on cornea and visual acuity in patients with diabetic retinopathy. (Pubmed Central) -  Oct 22, 2023   
    Intravitreal administration of anti-VEGF agents could cause a small but significant greater increase in CCT in PDR than in NPDR eyes in the early period. In patients with DR, no significant difference was found between conbercept and ranibizumab in the early effects on the visual acuity nor in the cornea.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date:  Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-na (clinicaltrials.gov) -  Oct 5, 2023   
    P=N/A,  N=102, Not yet recruiting, 
    Bevacizumab (0.625 N=52 --> 102 | Trial completion date: Aug 2025 --> Nov 2025 | Initiation date: Aug 2023 --> Nov 2023 | Trial primary completion date: Aug 2024 --> Nov 2024
  • ||||||||||  RC28-E / Rongchang Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Evaluation of RC28-E Injection in Diabetic Macular Edema (clinicaltrials.gov) -  Aug 31, 2023   
    P2,  N=156, Completed, 
    Needle revision of filtration bleb combined with anti-VEGF drugs is a safe and effective method for the treatment of filtration bleb dysfunction after surgery of glaucoma. Recruiting --> Completed | Trial completion date: Dec 2023 --> Jul 2023 | Trial primary completion date: Nov 2023 --> Jul 2023
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Trial completion date, Trial initiation date, Trial primary completion date:  Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-na (clinicaltrials.gov) -  Jul 12, 2023   
    P=N/A,  N=52, Not yet recruiting, 
    The aforementioned microvasculature changes should be considered when PRP or IVC is adopted in PDR long-term management. Trial completion date: Apr 2025 --> Aug 2025 | Initiation date: Apr 2023 --> Aug 2023 | Trial primary completion date: Apr 2024 --> Aug 2024
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
    Review, Journal:  Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases. (Pubmed Central) -  Jun 19, 2023   
    Consequently, there is a need to develop small molecule inhibitors of VEGFR to target ocular neovascularization diseases. This review summarizes the recent developments in potential VEGFR small molecule inhibitors for the targeted treatment of ocular neovascularization diseases, with the aim of providing insights for future studies on VEGFR small molecule inhibitors.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Journal:  Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy. (Pubmed Central) -  Jun 16, 2023   
    This review summarizes the recent developments in potential VEGFR small molecule inhibitors for the targeted treatment of ocular neovascularization diseases, with the aim of providing insights for future studies on VEGFR small molecule inhibitors. For postoperative effectiveness, group B had a significantly higher proportion of visual acuity that improved or remained unchanged than group D (P = 0.014), and groups A-C had lower proportions of postoperative bleeding than group D. The vitreous VEGF concentration of group B (67.04
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Enrollment open:  Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-na (clinicaltrials.gov) -  May 23, 2023   
    P=N/A,  N=52, Recruiting, 
    For postoperative effectiveness, group B had a significantly higher proportion of visual acuity that improved or remained unchanged than group D (P = 0.014), and groups A-C had lower proportions of postoperative bleeding than group D. The vitreous VEGF concentration of group B (67.04 Not yet recruiting --> Recruiting
  • ||||||||||  Journal:  Modern trends in anti-VEGF therapy for age-related macular degeneration (Pubmed Central) -  May 9, 2023   
    The molecule of this drug is a humanized immunoglobulin G antibody that acts on two key points of angiogenesis: VEGF-A and angiopoietin-2 (Ang-2). Thus, the strategy for advancing anti-VEGF therapy lies in the development of molecules with greater efficiency (better effect on newly formed vessels leading to resorption of exudate in the retina, under the neuroepithelium and under the retinal pigment epithelium), which allows not just to preserve vision, but to also significantly improve it when there is no macular atrophy.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Journal:  Effect of Intravitreal Conbercept Injection on Complications of Pars Plana Vitrectomy in Patients with Proliferative Diabetic Retinopathy. (Pubmed Central) -  Apr 28, 2023   
    Thus, the strategy for advancing anti-VEGF therapy lies in the development of molecules with greater efficiency (better effect on newly formed vessels leading to resorption of exudate in the retina, under the neuroepithelium and under the retinal pigment epithelium), which allows not just to preserve vision, but to also significantly improve it when there is no macular atrophy. IVC before PPV can reduce the level of VEGF-A in the vitreous body and reduce surgical complications.
  • ||||||||||  Subretinal Delivery of an AAV Gene Therapy Product Significantly Inhibited the Neovascularization in a Laser-Induced CNV Rhesus Model (Board No. 1384) -  Apr 21, 2023 - Abstract #ASGCT2023ASGCT_2038;    
    Currently available treatments for neovascular Age-related macular degeneration (wAMD) include Conbercept,Aflibercept, Ranibizumab, Faricimab and Bevacizumab which are antibodies targeting the VEGF axis...The purpose of this study is to develop a therapeutic strategy that have a long-lasting effect with reduced administration frequency, potentially even a single administration.We developed a gene therapy medication (KH631) that encodes anti-VEGF (Conbercept) transgene inside a rAAV8 vector (AAV8-Conbercept)...Laser modeling was conducted 28 days post injection for all the animals in both eyes; Two animals were laser injured and injected immediately with 0.5 mg/eye of Conbercept as positive controls. FL test was performed at week-4 post modeling, images show the representative images of fluorescein fundus angiography (FFA).
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Trial completion, Enrollment change, Trial completion date:  Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization (clinicaltrials.gov) -  Mar 30, 2023   
    P=N/A,  N=50, Completed, 
    Both 3?+?Q12W and 3?+?TAE regimens of IVC could result in improvement in visual and anatomical outcomes in PCV patients. Recruiting --> Completed | N=150 --> 50 | Trial completion date: Dec 2023 --> Jan 2023
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Review, Journal, HEOR, Cost-effectiveness, Cost effectiveness:  Cost-effectiveness analysis of myopia management: A systematic review. (Pubmed Central) -  Mar 20, 2023   
    Treating pathologic myopia with ranibizumab and conbercept were more cost-effective than PDT. Prevention of myopia progression is more cost-effective than treating pathologic myopia.